Radical Surgery for Advanced Gastric- or GEJ-cancer With Oligometastatic Dissmination to the Liver
ConditionSurvival
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAarhus University Hospital
About this trial
Offering treatment with potential to cure for participants with no such offer in today's standard treatment options, by offering metastatectomia and standard treatment with intention to cure i.e., neoadjuvant chemotherapy and gastrectomy for participants with gastric- og gastroeusofageal junction cancer. Including 20 participants from all 4 centres in Denmark able to perform the surgical procedures in question.
Endpoints: 2-year overall survival.
Eligibility criteria
Qualifiers
Age > 18.
Presence of primary T1-T4N0-N3M1 adenocarcinoma of the stomach or GEJ and max. 30% liver involvement.
Primary tumour resectable, based on imaging workup.
Surgical operable patients with ASA-score36 ≤ III and WHO performance status37 0-1.
Disqualifiers
Patient with non-resectable cancer.
Direct growth involving adjacent organs, i.e., pancreas, colon, blood vessels or bones.
Other malignant disease diagnosed or treated up to 2 years prior to inclusion, except non-aggressive cancers such as non-melanoma sin cancer.
Altered anatomy of the upper gastrointestinal tract due to previous surgery of the oesophagus, stomach, and duodenum.
Trial design
Treatments tested in this trial
- Metastatectomia and standard treatment for resectable disease.
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Aarhus University Hospital
Lead sponsor
Rigshospitalet, Denmark
Collaborator
Aalborg University Hospital
Collaborator
Odense University Hospital
Collaborator
Source ClinicalTrials.gov